Institutional Investors Co-Led Series B Financing of Amador Bioscience, a Global Translational Sciences and Clinical Pharmacology CRO

PLEASANTON, Calif.: PLEASANTON, Calif., Sept. 28, 2021 /PRNewswire/ -- Amador Bioscience, a contract research organization (CRO) that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies, today announced the completion of Series B financing to support its further global expansion. The financing was co-led by Sequoia Capital...

Click to view original post